Skip to main content
. 2009 Feb;174(2):460–474. doi: 10.2353/ajpath.2009.080462

Figure 7.

Figure 7

Fn14-TRAIL · pSBC21 treatment reduces the number of activated and cytokine-producing cells in spinal cords of MOG-challenged mice on days 7 and 14 of disease. Mice were sacrificed on days 7 or 14 of disease, and flow cytometry was performed on the mononuclear cells isolated from spinal cords of pSBC21 vector-only or Fn14-TRAIL · pSBC21-treated mice (three mice per group), as described in the Material and Methods. Live lymphocytes were gated based on forward and side scatter. CD8 and CD69 markers were measured on gated lymphocytes, and analysis of cells producing each of the cytokines shown was for gated CD4+ lymphocytes. Absolute cell numbers were calculated by multiplying the total number of live mononuclear cells times the percentage of each indicated cell type (determined by flow cytometry). Data are representative of three independent experiments with similar results. A and B: Percentage and absolute number of activated (CD69+) inflammatory cells on day 7 after MOG challenge. C and D: Percentage and absolute number of CD4+ and CD8+ cells, and of IFN-γ-, IL-17-, and IL-10-expressing cells (amid activated CD69+ cells or the total cell pool) on day 7 after MOG challenge. E and F: Percentage and absolute number of CD8+ cells and of IFN-γ-, IL-17-, and IL-10-expressing cells on day 14 after MOG challenge.